KID | Jotup

Pricing of Debt

Retrieved on:

星期三, 四月 10, 2024

KID, Regulation, Reproduction, Person, Property management

Any forwarding, distribution or reproduction of the Final Terms or the Offering Circular in whole or in part is prohibited.

Key Points:

Any forwarding, distribution or reproduction of the Final Terms or the Offering Circular in whole or in part is prohibited.
Failure to comply with this notice may result in a violation of the Securities Act or the applicable laws of other jurisdictions.
Manufacturer target market (EU MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels).
No EU PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in EEA or in the UK.

Air Lease Corporation Announces Pricing of Offering of €600 Million of Senior Unsecured Medium-Term Notes

Retrieved on:

星期四, 三月 21, 2024

Air Lease Corporation (NYSE: AL) (the “Company”) announced the pricing on March 20, 2024 of its offering of €600 million aggregate principal amount of 3.70% senior unsecured medium-term notes due April 15, 2030 (the “Notes”).

Key Points:

Air Lease Corporation (NYSE: AL) (the “Company”) announced the pricing on March 20, 2024 of its offering of €600 million aggregate principal amount of 3.70% senior unsecured medium-term notes due April 15, 2030 (the “Notes”).
The sale of the Notes is expected to close on March 27, 2024, subject to satisfaction of customary closing conditions.
Owners of the Notes will receive payments relating to the Notes in Euros.
BBVA, Deutsche Bank, J.P. Morgan, NatWest Markets, and Societe Generale are acting as joint book-running managers for the offering of the Notes.

OSSIAM STOXX EUROPE 600 ESG EQUAL WEIGHT NR: change of dealing deadline

Retrieved on:

星期三, 三月 13, 2024

KID, Prospectus, Dissemination, Security (finance)

The board of directors of the Company (the “Board”) would like to inform you that an amendment has been made to the prospectus of the Company (the “Prospectus”) in relation to the following sub-fund, such amendment to take effect as from 29 March 2024 (the “Effective Date”):

Key Points:

The board of directors of the Company (the “Board”) would like to inform you that an amendment has been made to the prospectus of the Company (the “Prospectus”) in relation to the following sub-fund, such amendment to take effect as from 29 March 2024 (the “Effective Date”):
Please find below a table setting out the current Dealing Deadline and the updated Dealing Deadline:
Copies of the Prospectus and the relevant key information document (KID) reflecting the above change will be available free of charge at the registered office of the Company, once available.
Should you disagree with the planned change mentioned above, you may redeem your shares, free of redemption charge until 28 March 2024 in accordance with the redemption procedure set out in the Prospectus.
On behalf of the Company,
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Omnicom Prices €600 Million Senior Notes Offering

Retrieved on:

星期三, 二月 28, 2024

Barclays, Issuer, J.P. Morgan & Co., Prospectus, Financial services, Person, OMC, Note, Investment, KID, Sale, New York Stock Exchange, Debt-to-GDP ratio, HSBC (United Kingdom), Application, Security (finance), Finance, HSBC Bank, BNP Paribas

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Omnicom (NYSE: OMC) and Omnicom Finance Holdings plc (the "Issuer"), a wholly owned indirect subsidiary of Omnicom, today announced the pricing of the Issuer's public offering of €600 million aggregate principal amount of 3.700% Senior Notes due 2032 (the "Notes").

Key Points:

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Omnicom (NYSE: OMC) and Omnicom Finance Holdings plc (the "Issuer"), a wholly owned indirect subsidiary of Omnicom, today announced the pricing of the Issuer's public offering of €600 million aggregate principal amount of 3.700% Senior Notes due 2032 (the "Notes").
The Notes will be fully and unconditionally guaranteed by Omnicom.
The Notes and the related guarantee will be the unsecured and unsubordinated obligations of the Issuer and Omnicom, respectively, and will rank equal in right of payment to all of their respective existing and future unsecured senior indebtedness.
No EEA or UK PRIIPs key information document (KID) has been prepared as the Notes are not available to retail in EEA or UK.

PuroClean Partners with Local Businesses and Kids In Distress (KID) To Create Holiday Magic, Collects Hundreds of Toys for Donation

Retrieved on:

星期三, 十二月 27, 2023

Online, Pasta, Partner, Marketing, Holiday, KID, City, Season, BurgerFi, Love, Magic, Child, Toy

TAMARAC, Fla., Dec. 27, 2023 /PRNewswire/ -- PuroClean, a leading brand in property restoration and remediation throughout the country, has recently wrapped up their PuroClean Cares™: Season of Giving toy drive campaign. The brand and local business partners generously donated to Kids In Distress to help support struggling families throughout South Florida who are unable to afford high-cost items and toys for their children and loved ones. Kids In Distress, Inc. (KID) is a nationally accredited organization dedicated to preventing child abuse, preserving families, and treating children who have been abused and neglected.

Key Points:

The brand and local business partners generously donated to Kids In Distress to help support struggling families throughout South Florida who are unable to afford high-cost items and toys for their children and loved ones.
Kids In Distress, Inc. (KID) is a nationally accredited organization dedicated to preventing child abuse, preserving families, and treating children who have been abused and neglected.
"We initiated this effort in hopes of bringing joy and cheer to our local communities this holiday season.
Partners include the owners and team members of the following local Southern Florida PuroClean locations; Ricardo Herdan, David Shiffman, Carlos Niemes, Joaquin Seminario, Kay Henriques and Hugo Urribarri.

EQS-News: ams OSRAM announces the offering of EUR 800 million equivalent senior notes as part of its recently presented financing plan

Retrieved on:

星期四, 十二月 14, 2023

AMERICA, OSRAM, AMS, Prospectus, Financial services, SALES, EUR, Nature, Person, Finance, SEC Rule 144A, Debt-to-GDP ratio, KID, Sale, Ams-OSRAM, EEA, Investment, Security (finance), Note

Premstaetten, Austria, and Munich, Germany (13 November 2023) – ams OSRAM (SIX: AMS) announced today the launch of an offering of EUR 800 million equivalent aggregate principal amount of senior unsecured notes, comprising euro denominated senior unsecured notes due March 2029 and dollar denominated senior unsecured notes due March 2029 (together, the "Notes") as part of its recently presented financing plan.

Key Points:

Premstaetten, Austria, and Munich, Germany (13 November 2023) – ams OSRAM (SIX: AMS) announced today the launch of an offering of EUR 800 million equivalent aggregate principal amount of senior unsecured notes, comprising euro denominated senior unsecured notes due March 2029 and dollar denominated senior unsecured notes due March 2029 (together, the "Notes") as part of its recently presented financing plan.
There will be no public offering of Notes in the United States of America.
Manufacturer target market (MIFID II product governance) for the Notes is eligible counterparties and professional clients only (all distribution channels).
This announcement may contain statements about ams OSRAM (the “Company”, and together with its subsidiaries the “Group”) that are or may be “forward-looking statements”.

Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds

Retrieved on:

星期三, 十一月 8, 2023

FOR, J. P. Morgan, EBITDA, Person, Mizuho, NOT, OR, BNP Paribas, KID, Linklaters, BBB, Media release, S&P, AND, CHF, Security (finance), Bank, Novartis, BAA2, EUR, EEA

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Key Points:

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 million
Basel, November 8, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of three highly successful inaugural Eurobonds, with total gross proceeds of EUR 2.0 billion.
Following a debut transaction in CHF last month, this issuance marks the entry of Sandoz into the EUR debt capital market.
Colin Bond, Sandoz CFO said: "These inaugural bonds represent a further milestone for Sandoz, establishing us firmly as a new issuer in the EUR bond market and creating a diversified and well-balanced financing profile from a currency and maturity perspective."
The proceeds, together with those from last month’s CHF issuance, will be used for the repayment of the EUR 2.4 billion bridge loan and for general corporate purposes.

Philips successfully prices offering of Notes for EUR 500 million to be used for repayment of existing debt, resulting in a debt-neutral effect

Retrieved on:

星期三, 八月 30, 2023

THERE IS NO INTENTION TO REGISTER ANY SECURITIES REFERRED TO HEREIN IN THE UNITED STATES OR TO CONDUCT A PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES.

Key Points:

THERE IS NO INTENTION TO REGISTER ANY SECURITIES REFERRED TO HEREIN IN THE UNITED STATES OR TO CONDUCT A PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES.
Any person who is not a relevant person should not act or rely on this press release or any of its contents.
Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels).
No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in EEA or UK.

Aker BP ASA announces pricing of Senior Notes Offering

Retrieved on:

星期四, 六月 8, 2023

FORNEBU, Norway, June 8, 2023 /PRNewswire/ -- Aker BP ASA (the "Company") is pleased to announce that it has priced its offering (the "Offering") of $500 million aggregate principal amount of 5.600% Senior Notes due 2028 (the "2028 Notes") at a price equal to 99.910% of the aggregate principal amount thereof and $1,000 million aggregate principal amount of its 6.000% Senior Notes due 2033 (the "2033 Notes") at a price equal to 99.762% of the aggregate principal amount thereof (the 2028 Notes and 2033 Notes together, the "Notes"). Interest will be payable semi-annually.

Key Points:

FORNEBU, Norway, June 8, 2023 /PRNewswire/ -- Aker BP ASA (the "Company") is pleased to announce that it has priced its offering (the "Offering") of $500 million aggregate principal amount of 5.600% Senior Notes due 2028 (the "2028 Notes") at a price equal to 99.910% of the aggregate principal amount thereof and $1,000 million aggregate principal amount of its 6.000% Senior Notes due 2033 (the "2033 Notes") at a price equal to 99.762% of the aggregate principal amount thereof (the 2028 Notes and 2033 Notes together, the "Notes").
The Offering is expected to close on or about June 13, 2023, subject to customary conditions precedent for similar transactions.
In connection with the Offering, the initial purchasers may engage in stabilizing transactions with a view to supporting the market price of the Notes at a level higher than that which might otherwise prevail.
No public offering of securities will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited.

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

Retrieved on:

星期四, 六月 1, 2023

THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).

Key Points:

Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases
THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.
More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).
"Our presentations at ASCO will illustrate how we're advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
"We're focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer."